Tomahawk, WI 06/23/2014 (Basicsmedia) – Global healthcare company Sanofi SA (ADR) (NYSE:SNY) and biopharmaceutical company Merrimack Pharmaceuticals Inc (NASDAQ:MACK) have reached an understanding allowing Merrimack to develop and commercialize monoclonal antibody drug MM-121.
MM-121 Global Rights
Merrimack said that it would regain global rights to develop, as well as, commercialize a monoclonal antibody drug, MM-121, meant to block ErbB3 activation in patients having Hereglin-positive tumors apart from improving treatments response to standard of care.
Sanofi SA (ADR) (NYSE:SNY) and Merrimack have finished a wide range of Phase two program for MM-121 drug that was meant to assess ErbB3 role in a number of indications of cancer in the neoadjuvant and metastatic settings. Merrimack said that it could identify that Herefulin is connected with the poor response in an advanced settings compared to standard of care treatment and that the addition of MM-121 might re-establish sensitivity among the most at-risk patients.
Merrimac also said that patients in these studies with positive Heregulin tumors experienced a statistically important reduction in the progression of risk when they were given a combination with MM-121. In approximately 30 – 50% of the patients tested, the company disclosed that Heregulin fuelled drug resistance conduits were found to be active. The company indicated that the trials data were presently recently during the American Society of Clinical Oncology Annual Meeting 2014.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) president and CEO Robert Mulroy said that it believed the data generated from the alliance validating the budding for MM-121 to support patients, who are at most risk for progression on current treatments. He said that reclaiming MM-121 is a prospect to make the most of its leadership position in the oncology companies, which are following ErbB3.
The company’s CEO also disclosed that it had already received feedback from its committed investigators and firmly believes the potential of MM-121. It indicated that the next step would be to discuss its study two data and the possible registration trail with the Food and Drug Administration or FDA.